POS0741 IMPACT OF ACTIVE LUPUS NEPHRITIS ON THE QUALITY OF LIFE OF PATIENTS FROM A LATIN AMERICAN LUPUS COHORT
Authors: R. Nieto, R. Quintana, D. C. Fernández Ávila, R. Serrano, G. Harvey, L. Hernández, K. Roberts, E. S. Palacios Santillan, N. Meras, C. Otaduy, E. Novatti, V. Arturi, B. Kisluk, L. González Lucero, E. Kerzberg, N. Pérez, C. Pisoni, P. Pirruccio, M. E. Crespo Espindola, A. C. D. O. E. S. Montandon, A. A. Gasparin, A. Duarte, L. Alvino, E. Bonfa, E. Figueiredo Neves Yuki, L. V. De Oliveira Martins, I. Guerra Herrera, M. Mimica Davet, L. De La Hoz Rueda, A. Cadena Bonfanti, R. Rivera, P. C. Alvarado, J. F. Jaramillo, J. Martínez, M. Moreno Alvarez, R. E. Sánchez Briones, M. Pérez Cristóbal, E. Martin Nares, Y. Juárez-Vicuña, Y. González Bello, J. O. González Enriquez, L. R. Aguilar Rivera, M. Duarte, P. Langjarth, W. Pérez Medina, A. Calvo Quiroz, T. Polanco Mora, C. Pizzarossa, G. Silveira, C. Reátegui-Sokolova, G. S. Alarcón, U. Sbarigia, F. Zazzetti, A. Orillion, G. Pons-Estel, B. Pons-Estel
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Lupus nephritis (LN) is one of the most common, serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. <h3>Objectives:</h3> To evaluate health-related quality of life (HRQoL) in patients with active LN at baseline and 12 months after treatment in relationship to the patients' renal response. <h3>Methods:</h3> GLADEL 2.0 is an observational prevalent and incident cohort initiated in 2019. Forty-four centers from 10 Latin-American countries enrolled patients ≥18 years of age who fulfilled the 1982/1997 American College of Rheumatology (ACR) and/or the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for Systemic lupus erythematosus (SLE). These patients were from four different groups according to the presence or not of LN. For this analysis, patients in Group II (prevalent inactive LN), III (prevalent active LN) and IV (incident LN, onset &lt; 3 months) and follow-up data at 12 months were included. Demographic, clinical manifestations, treatments, disease activity (SLEDAI-2k) and damage SLICC/ACR Damage Index (SDI) were examined. At baseline, HRQoL was assessed with the LupusQoL and compared by the presence of active or inactive LN. At 12 months, the LupusQoL was applied to the active LN patients as a function of their renal response. Partial and complete responses were defined according to EULAR/KDIGO: Complete clinical response (CCR): UPCR &lt; 0.5 g/g; Partial Clinical Response Criteria (PRC): ≥50% reduction in UPCR and No Response (NR): &lt;50% reduction in proteinuria. A descriptive analysis was performed. <h3>Results:</h3> Of the 1081 patients included in the cohort, 651 patients with LN were evaluated (423 with active and 228 with inactive disease). The active LN patients were predominantly women [569 (87.4%)], younger at cohort entry, of lower socioeconomic status, exhibited higher levels of unemployment, and had a higher SLEDAI than patients with inactive LN. As to the baseline LupusQoL, it was found to be worse in patients with active LN in all domains (Table 1). At 12 months, however, no differences were found between those patients who achieved complete/partial renal response versus those who did not (Table 2). <h3>Conclusion:</h3> At baseline, active LN patients showed a worse QoL compared to those with inactive LN. However, at 12 months no differences were found between patients who achieve or did not achieve a renal response. Future analyses with a larger number of follow-up patients would be necessary to provide conclusive data. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Medical writing support was provided by Panita Maturavongsadit, PhD, of Lumanity Communications Inc., and was funded by Janssen Global Services, LLC. <h3>Disclosure of Interests:</h3> Romina Nieto: None declared, Rosana Quintana: None declared, Diana Carolina Fernández Ávila: None declared, Rosa Serrano: None declared, Guillermina Harvey: None declared, Lucia Hernández: None declared, Karen Roberts: None declared, Erika S. Palacios Santillan: None declared, Nidia Meras: None declared, Cintia Otaduy: None declared, Elisa Novatti: None declared, Valeria Arturi: None declared, Boris Kisluk: None declared, Luciana González Lucero: None declared, Eduardo Kerzberg: None declared, Nicolás Pérez: None declared, Cecilia Pisoni: None declared, Paola Pirruccio: None declared, María Elena Crespo Espindola: None declared, Ana Carolina de Oliveira e Silva Montandon GSK, AstraZeneca, Andrese Aline Gasparin: None declared, Angela Duarte: None declared, Laissa Alvino: None declared, Eloisa Bonfa: None declared, Emily Figueiredo Neves Yuki: None declared, Lucas Victoria de Oliveira Martins: None declared, Iris Guerra Herrera: None declared, Milena Mimica Davet: None declared, Lizeth De La Hoz Rueda: None declared, Andrés Cadena Bonfanti: None declared, Roberth Rivera: None declared, Paola Coral Alvarado: None declared, John Fredy Jaramillo: None declared, José Martínez: None declared, Mario Moreno Alvarez: None declared, Reyna Elizabeth Sánchez Briones: None declared, Mario Pérez Cristóbal: None declared, Eduardo Martin Nares: None declared, Yaneli Juárez-Vicuña: None declared, Yelitza González Bello: None declared, Jose Octavio González Enriquez: None declared, Leonardo René Aguilar Rivera: None declared, Margarita Duarte: None declared, Patricia Langjarth: None declared, Wilkerson Pérez Medina: None declared, Armando Calvo Quiroz: None declared, Teresandris Polanco Mora: None declared, Carina Pizzarossa: None declared, Gonzalo Silveira: None declared, Cristina Reátegui-Sokolova: None declared, Graciela S. Alarcón: None declared, Urbano Sbarigia Johnson &amp; Johnson, Johnson &amp; Johnson Innovative Medicine, Federico Zazzetti Johnson &amp; Johnson, Johnson &amp; Johnson Innovative Medicine, Ashley Orillion Johnson &amp; Johnson, Johnson &amp; Johnson Innovative Medicine, Guillermo Pons-Estel AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, Bernardo Pons-Estel AstraZeneca, GSK, Janssen.